UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): | October 4, 2013 |
| |
| Enerpulse Technologies, Inc. |
| (Exact name of registrant as specified in its charter) |
| |
| Nevada | 000-54092 | 27-2969241 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
| 2451 Alamo Ave SE Albuquerque, New Mexico 87106 |
| (Address of principal executive offices) (zip code) |
| Registrant’s telephone number, including area code: | (505) 842-5201 |
| | |
| L2 Medical Development Company |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Name Change
In connection with L2 Medical Development Company’s (the “Company”) receipt of approval from the Financial Industry Regulatory Authority (“FINRA”), effective October 4, 2013, the Company amended and restated its Articles of Incorporation to change its name from “L2 Medical Development Company” to “Enerpulse Technologies, Inc.” (the “Name Change”).
The full text of the amendment to the Company’s Articles of Incorporation to give effect to the Name Change is filed herewith as Exhibit 3.1 and incorporated herein by reference.
SECTION 8 – OTHER EVENTS
Item 8.01 Other Events.
Symbol Change
In connection with the Name Change described in Item 5.03 above, FINRA assigned the Company a new stock symbol, “ENPT”. This new symbol took effect at the open of business on October 4, 2013.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
Exhibit No. | Exhibit Description |
| 3.1 | Text of Amendment to Articles of Incorporation |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | |
| | | | | L2 Medical Development Company |
| | | | |
| Date: October 4, 2013 | | | | By: | | /s/ Joseph E. Gonnella |
| | | | | Name: | | Joseph E. Gonnella |
| | | | | Title: | | Chief Executive Officer |
